| Prev Close | 87.59 |
| Open | 88.17 |
| Day Low/High | 86.73 / 88.17 |
| 52 Wk Low/High | 62.55 / 101.28 |
| Volume | 8.76M |
AbbVie, Inc. (ABBV)
87.13
0.46
0.53
NYSE
| Exchange | NYSE |
| Shares Outstanding | 1764.83B |
| Market Cap | 153.35B |
| P/E Ratio | 74.91 |
| Div & Yield | N.A. (N.A) |
Latest News
Weakening Dollar, Fiscal Relief Gridlock, Walmart+, Trading Albemarle
Also, interpreting Tuesday's market, Covid-19 vaccine update, and manufacturing growth.
A Healthy Dose of Vaccine and Pharmaceutical Plays
6 favorite stocks and ETFs in the biotech and pharmaceutical sector, including a diversified basket of Covid-19 vaccine names.
Stay Patient With AbbVie
I would continue to hold ABBV, and here's why.
2 Biotech Stocks to Buy on Solid Q2 Results
Covid-19 has had a big impact on this sector, but these names have strong catalysts going into the next quarter.
Let's Not Overlook AbbVie's Q2 Beat
There is no thought of selling here and now, even with politicized pressure on the industry.
Grotesque GDP, So Much for Rotation, Amazon Goes Wild: Market Recon
Plus, it could be quite a while before the labor market can absorb all those people who are out of jobs.
7 Drug Stocks With the Right Medicine for Investors
These pharmaceutical favorites continue to make progress on a number of fronts including a Covid-19 vaccine.
SPACs Aren't Just for Trading: 2 Attractive Buy and Hold Opportunities
I like putting some of my money with incredibly successful folks who are well-connected and have a history of success.
AbbVie Is Concocting a Formula for a Breakout
Here's an updated strategy for ABBV, which could see new highs soon.
The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance
I have always liked the aggressive management.
The Charts of AbbVie Can Reach New Heights
A lifting on the moratorium on elective procedures could be a big win for ABBV.
Jim Cramer: This Opening Is the Beginning of the End of the Healthcare Recession
What's really driving the market, what's making the Nasdaq roar? Tech and science, that's what.
Markets Test Support Levels, Amazon Earnings, Calibrating for Covid-19
The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.
Jim Cramer: I Don't Think Covid-19 Is Invincible
When it's beaten you will wish you own stocks, especially the stocks that are right now lethal to your portfolio.
A New Technical Strategy for AbbVie
Let's check out the charts of ABBV.
Jim Cramer: Finding Any Stocks With No Hair?
After a company reports we all know what's wrong, it's immunized. And that's when you can buy.
This Health Care Dividend King Offers a Remedy for Hopeless Investors
JNJ should survive a recession and prove in demand in a health crisis.
These Are the Times We Live In
Here again is my approach and my three stock groups: 'rebound', 'revenue' and 'virus'.
Jim Cramer: Panicking Never Made Anyone a Dime, but These Will
Here are six companies that should come through in the tough times ahead.
Jim Cramer: Let's See Who's Safe, Who Isn't
You can use these wild market swings to your advantage by identifying 'safe' companies you want to own and then buying their stocks in stages.
Jim Cramer: Rate Cut No Cure for Coronavirus
But don't throw up your arms yet -- here are names that could be golden opportunities.
Jim Cramer: I Don't Know Where It Will Bottom, I Do Know What to Buy and Sell
This is the time to high grade your portfolio, take some losses and move to better stocks.
AbbVie Could Be One of the Stocks That Recovers Before Others
Let's review the charts and indicators.
Three Strategies for Income Investors
For reliable income, a portfolio strategy generating monthly payouts, an opportunity in dividend kings, and favorites among taxable bond funds.
Coronavirus Spreads, Reducing 'Big Oil', 4 Stocks to Watch, Adding Store Capital
Newly confirmed cases of the Covid-19 virus spiked from Hubei Province in China, where the city of Wuhan is located. The number of related deaths increased as well.
Tech Based Rally, Real-Life Virus, Powell Speaks, Tracking 5 Stocks
This rally has been industry, not sector led, and it is all based on technology, whether or not market leaders reside within the Tech sector or not.
Watch These Biotech Names on Strong Earnings
Merger activity is the number 1 driver I am watching for biotech growth.
